Retapamulin: Focus on its use in the treatment of uncomplicated superficial skin infections and impetigo

Expert Review of Dermatology

Volumn 5, Issue 5, 2010, Pages 505-517

  Jacobs, Michael R ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

impetigo; pleuromutilin; retapamulin; Staphylococcus aureus; Streptococcus pyogenes; superficial skin infections

Indexed keywords

CEFALEXIN; FUSIDIC ACID; PLACEBO; PLEUROMUTILIN; PSEUDOMONIC ACID; RETAPAMULIN;

ANTIMICROBIAL ACTIVITY; APPLICATION SITE IRRITATION; BACTERIAL SKIN DISEASE; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MARKETING; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ECZEMA; EPISTAXIS; ERADICATION THERAPY; FEVER; HEADACHE; HUMAN; IMPETIGO; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NAUSEA; NONHUMAN; PATIENT COMPLIANCE; PLASMA PROTEIN BINDING; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; QT PROLONGATION; REVIEW; RHINOPHARYNGITIS; SECONDARY INFECTION; SIDE EFFECT; SKIN ALLERGY; SKIN INFECTION; SKIN INJURY; SKIN IRRITATION; SNEEZING; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME;

EID: 77958062971     PISSN: 17469872     EISSN: None     Source Type: Journal    
DOI: 10.1586/edm.10.45     Document Type: Review

References (61)

1. Gelmetti C. Local antibiotics in dermatology. Dermatol. Ther. 21(3), 187-195 (2008).
2. Stevens DL, Bisno AL, Chambers HF et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin. Infect. Dis. 41(10), 1373-1406 (2005).
3. Yun HJ, Lee SW, Yoon GM et al. Prevalence and mechanisms of low- and high-level mupirocin resistance in staphylococci isolated from a Korean hospital. J. Antimicrob. Chemother. 51(3), 619-623 (2003).
4. Retapamulin for impetigo and other infections. Drug Ther. Bull. 46(10), 76-79 (2008).
5. Moran GJ, Krishnadasan A, Gorwitz RJ et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N. Engl. J. Med. 355(7), 666-674 (2006).
6. Koning S, van der Wouden JC. Treatment for impetigo. BMJ 329(7468), 695-696 (2004).
7. Groner A, Laing-Grayman D, Silverberg NB. Outpatient pediatric community-acquired methicillin-resistant Staphylococcus aureus: A polymorphous clinical disease. Cutis 81(2), 115-122 (2008).
8. Mongkolrattanothai K, Mankin P, Raju V, Gray B. Surveillance for mupirocin resistance among methicillin-resistant Staphylococcus aureus clinical isolates. Infect. Control Hosp. Epidemiol. 29(10), 993-994 (2008).
9. Lio PA, Kaye ET. Topical antibacterial agents. Infect. Dis. Clin. North Am. 18(3), 717-733, x (2004).
10. Simor AE, Stuart TL, Louie L et al. Mupirocin-resistant, methicillin-resistant Staphylococcus aureus strains in Canadian hospitals. Antimicrob. Agents Chemother. 51(11), 3880-3886 (2007).
11. Upton A, Lang S, Heffernan H. Mupirocin and Staphylococcus aureus: A recent paradigm of emerging antibiotic resistance. J. Antimicrob. Chemother. 51(3), 613-617 (2003).
12. Powell JP, Wenzel RP. Antibiotic options for treating community-acquired MRSA. Expert Rev. Anti. Infect. Ther. 6(3), 299-307 (2008).
13. Robinson DA, Sutcliffe JA, Tewodros W, Manoharan A, Bessen DE. Evolution and global dissemination of macrolide-resistant group A streptococci. Antimicrob. Agents Chemother. 50(9), 2903-2911 (2006).
14. Richter SS, Heilmann KP, Dohrn CL et al. Increasing telithromycin resistance among Streptococcus pyogenes in Europe. J. Antimicrob. Chemother. 61(3), 603-611 (2008).
15. Drews J, Georgopoulos A, Laber G, Schutze E, Unger J. Antimicrobial activities of 81.723 hfu, a new pleuromutilin derivative. Antimicrob. Agents Chemother. 7(5), 507-516 (1975).
16. Anchel M. Chemical studies with pleuromutilin. J. Biol. Chem. 199(1), 133-139 (1952).
17. Kavanagh F, Hervey A, Robbins WJ. Antibiotic substances from basidiomycetes: VIII. Pleurotus mutilus (Fr.) sacc. and Pleurotus passeckerianus pilat. Proc. Natl Acad. Sci. USA 37(9), 570-574 (1951).
18. Jones RN, Pfaller MA, Rhomberg PR, Walter DH. Tiamulin activity against fastidious and nonfastidious veterinary and human bacterial isolates: Initial development of in vitro susceptibility test methods. J. Clin. Microbiol. 40(2), 461-465 (2002).
19. Lobova D, Smola J, Cizek A. Decreased susceptibility to tiamulin and valnemulin among Czech isolates of Brachyspira hyodysenteriae. J. Med. Microbiol. 53(Pt 4), 287-291 (2004). (Pubitemid 38453432)
20. Hannan PC, Windsor HM, Ripley PH. In vitro susceptibilities of recent field isolates of Mycoplasma hyopneumoniae and Mycoplasma hyosynoviae to valnemulin (Econor), tiamulin and enrofloxacin and the in vitro development of resistance to certain antimicrobial agents in Mycoplasma hyopneumoniae. Res. Vet. Sci. 63(2), 157-160 (1997).
21. Hu C, Zou Y. Mutilins derivatives: From veterinary to human-used antibiotics. Mini. Rev. Med. Chem. 9(12), 1397-1406 (2009).
22. Egger H, Reinshagen H. New pleuromutilin derivatives with enhanced antimicrobial activity. II. Structure-activity correlations. J. Antibiot. (Tokyo) 29(9), 923-927 (1976).
23. Springer DM, Sorenson ME, Huang S et al. Synthesis and activity of a C-8 keto pleuromutilin derivative. Bioorg. Med. Chem. Lett. 13(10), 1751-1753 (2003).
24. Scangarella-Oman NE, Shawar RM, Bouchillon S, Hoban D. Microbiological profile of a new topical antibacterial: Retapamulin ointment 1%. Expert Rev. Anti. Infect. Ther. 7(3), 269-279 (2009).
25. Shawar R, Scangarella-Oman N, Dalessandro M et al. Topical retapamulin in the management of infected traumatic skin lesions. Ther. Clin. Risk Manag. 5(1), 41-49 (2009).
26. Moody MN, Morrison LK, Tyring SK. Retapamulin: What is the role of this topical antimicrobial in the treatment of bacterial infections in atopic dermatitis? Skin Therapy Lett. 15(1), 1-4 (2010).
27. Nagabushan H. Retapamulin: A novel topical antibiotic. Indian J. Dermatol. Venereol. Leprol. 76(1), 77-79 (2010).
28. Yan K, Madden L, Choudhry AE et al. Biochemical characterization of the interactions of the novel pleuromutilin derivative retapamulin with bacterial ribosomes. Antimicrob. Agents Chemother. 50(11), 3875-3881 (2006).
29. Davidovich C, Bashan A, Auerbach-Nevo T et al. Induced-fit tightens pleuromutilins binding to ribosomes and remote interactions enable their selectivity. Proc. Natl Acad. Sci. USA 104(11), 4291-4296 (2007).
30. Champney WS, Rodgers WK. Retapamulin inhibition of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells. Antimicrob. Agents Chemother. 51(9), 3385-3387 (2007).
31. Long KS, Hansen LH, Jakobsen L, Vester B. Interaction of pleuromutilin derivatives with the ribosomal peptidyl transferase center. Antimicrob. Agents Chemother. 50(4), 1458-1462 (2006).
32. Jones RN, Fritsche TR, Sader HS, Ross JE. Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci. Antimicrob. Agents Chemother. 50(7), 2583-2586 (2006).
33. Pankuch GA, Lin G, Hoellman DB et al. Activity of retapamulin against Streptococcus pyogenes and Staphylococcus aureus evaluated by agar dilution, microdilution, E-test, and disk diffusion methodologies. Antimicrob. Agents Chemother. 50(5), 1727-1730 (2006).
34. Goldstein EJ, Citron DM, Merriam CV et al. Comparative in vitro activities of retapamulin (SB-275833) against 141 clinical isolates of Propionibacterium spp., including 117 P. acnes isolates. Antimicrob. Agents Chemother. 50(1), 379-381 (2006).
35. Rittenhouse S, Biswas S, Broskey J et al. Selection of retapamulin, a novel pleuromutilin for topical use. Antimicrob. Agents Chemother. 50(11), 3882-3885 (2006).
36. Scangarella N, Jakielaszek C, McCloskey L et al. Analysis of the antibacterial activity of retapamulin against 10,595 isolates of Staphylococcus aureus, Streptococcus pyogenes and Streptococcus agalactiae from pre-clinical, global surveillance and clinical studies. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA, 17-20 September (2007) (Abstract E-2089).
37. Scangarella-Oman N, Naderer O, Anderson M et al. Antibacterial activity of retapamulin and comparators against nasal and pharyngeal Staphylococcus aureus isolates recovered from a clinical trial investigating the efficacy of retapamulin in nasal decolonization. Present at: 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, USA, 25-28 October (2008) (Abstract C1-3840).
38. Woodford N, Afzal-Shah M, Warner M, Livermore DM. In vitro activity of retapamulin against Staphylococcus aureus isolates resistant to fusidic acid and mupirocin. J. Antimicrob. Chemother. 62(4), 766-768 (2008).
39. Johnson B, Jordan A, Bouchillon S et al. In vitro activity of retapamulin (SB-275833), a novel topical antimicrobial against 3,486 gram-positive isolates associated with skin and skin structure infections (SSSIs) from 14 sites in North America. Present at: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA, 16-19 December (2005) (Abstract F-2050).
40. Traczewski MM, Brown SD. Proposed MIC and disk diffusion microbiological cutoffs and spectrum of activity of retapamulin, a novel topical antimicrobial agent. Antimicrob. Agents Chemother. 52(11), 3863-3867 (2008).
41. Rittenhouse S, Singley C, Hoover J, Page R, Payne D. Use of the surgical wound infection model to determine the efficacious dosing regimen of retapamulin, a novel topical antibiotic. Antimicrob. Agents Chemother. 50(11), 3886-3888 (2006).
42. Kosowska-Shick K, Clark C, Credito K et al. Single- and multistep resistance selection studies on the activity of retapamulin compared to other agents against Staphylococcus aureus and Streptococcus pyogenes. Antimicrob. Agents Chemother. 50(2), 765-769 (2006).
43. Gentry DR, Rittenhouse SF, McCloskey L, Holmes DJ. Stepwise exposure of Staphylococcus aureus to pleuromutilins is associated with stepwise acquisition of mutations in rplC and minimally affects susceptibility to retapamulin. Antimicrob. Agents Chemother. 51(6), 2048-2052 (2007).
44. Gentry DR, McCloskey L, Gwynn MN et al. Genetic characterization of Vga ABC proteins conferring reduced susceptibility to pleuromutilins in Staphylococcus aureus. Antimicrob. Agents Chemother. 52(12), 4507-4509 (2008).
45. Long KS, Poehlsgaard J, Kehrenberg C, Schwarz S, Vester B. The Cfr rRNA methyltransferase confers resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A antibiotics. Antimicrob. Agents Chemother. 50(7), 2500-2505 (2006).
46. Arias CA, Vallejo M, Reyes J et al. Clinical and microbiological aspects of linezolid resistance mediated by the cfr gene encoding a 23S rRNA methyltransferase. J. Clin. Microbiol. 46(3), 892-896 (2008).
47. Mendes RE, Deshpande LM, Castanheira M et al. First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob. Agents Chemother. 52(6), 2244-2246 (2008).
48. Miller K, Dunsmore CJ, Fishwick CW, Chopra I. Linezolid and tiamulin cross-resistance in Staphylococcus aureus mediated by point mutations in the peptidyl transferase center. Antimicrob. Agents Chemother. 52(5), 1737-1742 (2008).
49. Chosidow O, Oranje AP, Sacchidanand S et al. Retapamulin as a novel treatment for impetigo: Results of a Phase III, randomized trial of efficacy and safety versus fusidic acid. Present at: 15th Congress of the European Academy of Dermatology and Venereology. Rhodes, Greece 4-8 October (2006) (Abstract PO41.11).
50. Oranje AP, Chosidow O, Sacchidanand S et al. Topical retapamulin ointment, 1%, versus sodium fusidate ointment, 2%, for impetigo: A randomized, observer-blinded, noninferiority study. Dermatology 215(4), 331-340 (2007).
51. van der Wouden JC, Koning S, Chosidow O et al. Evaluation of retapamulin, a novel, broad-spectrum, topical antibacterial, for the treatment of impetigo: Results of a placebo-controlled, randomized, double-blind, efficacy and safety trial. Present at: 15th Congress of the European Academy of Dermatology and Venereology. Rhodes, Greece 4-8 October (2006) (Abstract PO41.74).
52. Koning S, van der Wouden JC, Chosidow O et al. Efficacy and safety of retapamulin ointment as treatment of impetigo: Randomized double-blind multicentre placebo-controlled trial. Br. J. Dermatol. 158(5), 1077-1082 (2008).
53. Free A, Roth E, Dalessandro M et al. Retapamulin ointment twice daily for 5 days vs oral cephalexin twice daily for 10 days for empiric treatment of secondarily infected traumatic lesions of the skin. Skinmed 5(5), 224-232 (2006).
54. Parish LC, Jorizzo JL, Breton JJ et al. Topical retapamulin ointment (1%, wt/wt) twice daily for 5 days versus oral cephalexin twice daily for 10 days in the treatment of secondarily infected dermatitis: Results of a randomized controlled trial. J. Am. Acad. Dermatol. 55(6), 1003-1013 (2006).
55. Naderer OJ, Anderson M, Roberts K et al. Nasal decolonization of persistent Staphylococcus aureus (SA) carriers with twice daily application of retapamulin ointment, 1%, (RET) for 3 or 5 Days. Present at: 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, USA, 25-28 October (2008) (Abstract L-1492).
56. Schalock PC. Allergic contact dermatitis to retapamulin ointment. Contact Dermatitis 61(2), 126 (2009).
57. Warshaw EM, Toby Mathias CG, Baker DR. Allergic contact dermatitis from retapamulin ointment. Dermatitis 20(4), 220-221 (2009).
58. Baker DE. New drugs approved by the FDA. Hosptial Pharmacy 42(6), 554-561 (2007).
59. Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48(1), 1-12 (2009).
60. Calfee DP, Salgado CD, Classen D et al. Strategies to prevent transmission of methicillin-resistant Staphylococcus aureus in acute care hospitals. Infect. Control Hosp. Epidemiol. 29(Suppl. 1), S62-S80 (2008).
61. McConeghy KW, Mikolich DJ, LaPlante KL. Agents for the decolonization of methicillin-resistant Staphylococcus aureus. Pharmacotherapy 29(3), 263-280 (2009).